Board summary
Key figures
39,176
Registered population
66.5% aged 18–64
19.6%
Aged 65+
ICB 19.0% · England 17.9%
7.6%
Ethnic minority (non-White)
3.5% Asian · England 9.6%
20.4%
In IMD quintile 1
ICB 31.9% · England 21.0%
~5,175
Core20 residents (est.)
Resident basis; registered basis ~8,648 · see page 3
5,898
Hypertension register
+3.50% in 3 yrs · England +5.60%
611
SMI register
16.2% of Cheshire West and Chester (LAD)'s
827
COPD register
Reviews -8.34% in 3 yrs
Forecast to 2030
6,543
Hypertension patients, 2030
+645 on today
65.2%
QRISK ≥20% on statins, 2030
+0.66pp over 3 yrs
5.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Respiratory reviews and smoking offers declined.
COPD annual reviews fell 8.3% over three years (England +2.8%), asthma reviews reached 64.1% (about 900 unreviewed), and smoking support offers fell 8.2 pp.
Age-five boosters and cervical screening trail.
Age-5 MMR dose 2 is 85.1% (below the 95.0% target by 9.9 pp), 4-in-1 is 83.6%, and younger cervical screening is 61.2% (LAD 72.1%).
Cardiovascular and diabetes control exceed England.
Hypertension treatment to target is 72.4% (England 70.3%), non-frail diabetes HbA1c control is 59.4% (England 57.4%), and 12-month 6-in-1 coverage reaches 98.4%.
Population, age and ethnicity
Older adults represent 19.6% of patients alongside 26 care homes in the catchment
Across 39,176 registered patients in six practices, 19.6% are aged 65+ (7,685 patients; England 17.9%; LAD 20.3%; ICB 19.0%), 66.5% are aged 18-64 (England 62.7%), and 13.9% are aged 0-17 (England 19.6%). Learning disability prevalence is 0.6% (220 patients; England 0.6%). Census resident figures show 7.6% ethnic minority population (Asian 3.5%, Mixed 2.0%, Black 1.1%, Other 1.0%; White 92.4%), exceeding LAD (2.0% Asian) and ICB (2.8%) but below England (9.6%). Census data reflects resident areas rather than practice-registered lists.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire West and Chester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire West and Chester LA) | 2,109 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire West and Chester LA) | 893 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire West and Chester LA) | 14.9 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 20.4%, exceeding the local authority average of 15.7%
Core20 cohort (IMD quintile 1) is 20.4% at PCN level, above Cheshire West and Chester (LAD) (15.7%), below NHS Cheshire and Merseyside Integrated Care Board (31.9%) and below England (21.0%). This is above the comparator, which may reflect need or recording; check which before changing capacity.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
611
SMI register
1.52% recorded prevalence
220
Learning disability register
0.55% recorded prevalence
26
Care homes, 1,068 beds
In the PCN catchment
9.6%
Provide unpaid care
Cheshire West and Chester (LAD), Census 2021
Recorded severe mental illness prevalence is 1.5% (611 patients), above Cheshire West and Chester LAD (1.0%), ICB (1.1%), and England (1.0%). The PCN catchment includes 26 care homes with 1,068 beds, though resident registrations are unconfirmed. Cheshire West and Chester local authority rough sleeping snapshot was 29 in 2025. Recorded SMI prevalence of 1.5% exceeds the England average of 1.0% across the registered population.
Severe mental illness: physical health checks
SMI prevalence is 1.5% (England 1.0%). Recorded blood pressure is 84.7% (England 83.4%) and BMI is 84.5% (England 82.1%), but smoking cessation offers fell 8.2 pp over three years to 88.0% (England 94.2%, +0.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,898
Hypertension register
+3.50%
Register growth, 3 yrs
Cheshire West and Chester (LAD) +6.60% · England +5.60%
+0.08pp
BP control, under 80
≤140/90 · −1.68pp aged 80+
+645
More patients by 2030
Forecast 6,543 (15.68%)
Hypertension case-finding and control
Hypertension: QOF prevalence is 14.6% at PCN level, below Cheshire West and Chester (LAD) (17.0%), below NHS Cheshire and Merseyside Integrated Care Board (16.8%) and below England (15.2%). Recorded hypertension is lower than comparators, which may reflect population age structure; case-finding review would test whether under-detection contributes.
Lipids and statins
Patients with QRISK ≥ 20% treated with lipid lowering therapy is 63.9% at PCN level, above Cheshire West and Chester (LAD) (63.8%), above NHS Cheshire and Merseyside Integrated Care Board (63.2%) and above England (63.6%). Lipid-lowering coverage is above the comparator, so the priority is keeping reach and reviewing who remains untreated.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 59,529 | £1.70 | £1.71 | £1.86 | £101,199 |
| Cardiovascular (all), 2025 | 83,506 | £6.09 | £4.37 | £3.33 | £508,552 |
Cost per item for Lipid-regulating drugs 2026 is £1.70 at PCN level, above Cheshire West and Chester (LAD) (£1.44), below NHS Cheshire and Merseyside Integrated Care Board (£1.71) and below England (£1.86). Unit cost is above the local authority comparator but below England and the ICB; formulary review would clarify cost drivers.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.02%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.35%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.0% (827 patients); reviews reached 73.3% (LAD 71.0%; ICB 74.6%; England 76.4%), falling 8.3% over three years (England +2.8%). Asthma prevalence is 6.5% (2,518 patients); reviews fell 2.0% over three years to 64.1% (England 65.7%, +4.4%), leaving about 900 unreviewed patients. Asthma prescribing for ages 5-19 is 2,033 items per 1,000 (England 1,488). Practice recall audits would test whether this reflects administrative gaps.
Cancer register and children's immunisation
Cancer register prevalence is 4.3% (1,746 patients), above England (3.8%). Childhood immunisation meets the 95.0% target at 12 months for 6-in-1 at 98.4% (England 91.0%), but age-5 boosters fall short: 4-in-1 is 83.6% (11.4 pp below target) and MMR dose 2 is 85.1% (9.9 pp below target, and 4.5 pp below dose 1 in the same cohort). Cohort audit would test if this reflects recall attrition.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
At PCN level, cervical screening coverage for women aged 25-49 is 61.2%, trailing Cheshire West and Chester LAD (72.1%) and England (66.8%), after a 3-year change of -3.2% (England -1.0%). In contrast, breast screening rose +14.4% to 73.5% (England 69.9%). Across the wider system, 55.5% of cancers with a known stage in NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2 in 2022 (7,482 of 13,490; England 55.3%), with 72.8% staged overall (13,490 of 18,522), trailing the 75.0% national ambition by 2028 (about 2,640 extra early cases needed; ICB data, not PCN performance). Persistent cervical screening gaps may delay detection unless primary care recall is expanded.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Countess of Chester Hospital NHS Foundation Trust achieved 87.4% on the 28-day faster diagnosis standard (standard 75.0%), ahead of North Cheshire and Mersey NHS Foundation Trust (80.2%), Wirral University Teaching Hospital NHS Foundation Trust (74.7%), the ICB (77.2%), and England (79.3%). On 62-day treatment, Countess reached 83.3% (standard 85.0%), below North Cheshire and Mersey (83.7%) but above Wirral (77.6%), the ICB (76.2%), and England (71.2%). In diagnostics, 11.3% of MRI and 19.1% of ultrasound patients waited 6+ weeks (England 21.4% and 19.6%). Acute diagnostic turnaround remains comparatively strong despite specific modality backlogs.
| Pathways within standard (%) | Countess of Chester | North Cheshire and Mersey | Wirral | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 87.37 | 80.21 | 74.71 | 77.25 | 79.32 |
| 31-day treatment (96%) | 93.48 | 98.17 | 92.53 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.28 | 83.67 | 77.65 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Countess of Chester | North Cheshire and Mersey | Wirral | England |
|---|---|---|---|---|
| MRI | 11.26 | 0.53 | 1.54 | 21.40 |
| CT | 4.18 | 2.32 | 1.55 | 9.92 |
| Echocardiography | 31.44 | 28.04 | 5.07 | 28.48 |
| Colonoscopy | 26.44 | 15.98 | 32.81 | 30.83 |
| Gastroscopy | 27.52 | 20.24 | 17.73 | 29.02 |
| All 15 DM01 tests | 20.16 | 6.34 | 5.02 | 23.14 |
| Community services activity | Cheshire West and Chester residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 47,655 | 541,280 |
| Referrals | 10,325 | 97,150 |
| Patients with a contact | 18,585 | 146,240 |
Community services (residents of Cheshire West and Chester), Jun 2026 (provisional). In the provisional June 2026 community services dataset for Cheshire West and Chester LAD residents, adults aged 65+ accounted for 52.7% of all recorded contacts (25,095 of 47,655). With 52.7% of community contacts involving older adults, integrated primary care coordination remains critical.
Practice variation and patient experience
Practice phone access spans 43.5 pp and overall satisfaction varies by 28.4 pp
In 2025/26, QOF overall achievement ranged from 62.0% at St Werburgh's Medical Practice Homeless to 98.2% at Fountains Medical Practice (England 92.5%). Vaccination achievement spanned 84.1 pp, from 0.0% at St Werburgh's to 84.1% at Fountains, with The Elms Medical Centre reaching 18.4% (England 55.2%). High clinical scores elsewhere may mask local immunisation gaps.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| St Werburgh's | 19 | 0.0 | 100.0% | 69.8% | 100.0% |
| Fountains Medical | 103 | 10.9 | 56.5% | 75.8% | 84.7% |
| Elms | 106 | 26.6 | 66.8% | 65.0% | 83.7% |
| Northgate Village | 102 | 26.3 | 79.1% | 75.4% | 81.5% |
| Northgate | 99 | 27.0 | 66.2% | 84.3% | 79.7% |
| Garden Lane | 113 | 16.3 | 68.6% | 73.3% | 71.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twenty-one of 25 tracked three-year changes trail England, led by annual reviews
Twenty-one of 25 tracked three-year changes trail England. The largest relative lag is in annual COPD reviews, falling 8.3% while England rose +2.8%. In percentage-point trends, smoking cessation support offers fell 8.2 pp (England +0.1 pp) to 88.0% (England 94.2%), and psychosis alcohol recording fell 4.5 pp (England +5.4 pp) to 78.4%. Conversely, three-year relative strengths include breast screening coverage, rising +14.4% (England +8.4%), and non-frail diabetes HbA1c control to 58 mmol/mol or less, rising +7.3% (England +4.4%). Annual review and lifestyle recording have lagged national trajectories.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Alcohol record (psychosis)
Smoking support (SMI)
Heart failure reviews
Asthma reviews
Breast screening (53-70)
Diabetes HbA1c control
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire West and Chester (LAD) | Asset | PCN | Cheshire West and Chester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 26 (1,068 beds) | n/a | Schools (catchment) | 73 | n/a |
| Children's centres | 3 | 15 | Places of worship | 61 | 231 |
| Libraries | n/a | 16 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 12 | 70 |
| Primary academies | 7 | 46 | Special schools | n/a | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Pre-school booster recall and catch-up
At age 5, MMR dose 2 is 85.1% (below the 95.0% target by 9.9 pp, and 4.5 pp below dose 1 at 89.6% across 67 children) and 4-in-1 is 83.6% (below by 11.4 pp). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Respiratory review and smoking support recall
Asthma reviews cover 64.1% of 2,518 patients (England 65.7%; about 900 unreviewed after falling 2.0%), COPD reviews fell 8.3% to 73.3%, and smoking cessation offers fell 8.2 pp to 88.0% (England 94.2%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Younger-cohort cervical screening outreach
Cervical screening coverage in women aged 25-49 is 61.2%, below Cheshire West and Chester LAD (72.1%, by 10.9 pp), the ICB (68.5%, by 7.3 pp) and England (66.8%, by 5.6 pp), falling 3.2% over 3 years. Low cost, quick to run.
Evidence base: uptake is the delivery measure of the national cancer screening programme; distance to the acceptable and achievable standards is the outreach target.
Policy anchor: Shift 3: sickness to prevention; Eliminate cervical cancer by 2040.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register audit (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Smoking cessation offer audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Pre-school booster catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Primary care access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Pre-school booster recall and catch-up (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Respiratory review and smoking support recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD patients with a review in the last 12 months | Core20PLUS5 respiratory | PCN |
| Option 3 · Younger-cohort cervical screening outreach (p12) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
